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Angiotensin converting enzyme 2 (ACE2) is a key element in the protective arm of the renin 
angiotensin system (RAS) (1,2). It was discovered 20 years ago when it was found to possess 
over 60% similarity to ACE (3,4). However, the active sites of ACE and ACE2 differ and 
accordingly, ACE inhibitors do not inhibit activity of ACE2 (5). ACE2 is a glycoprotein 
metalloprotease that exists in 2 forms: membrane-bound and soluble (3,4,6). The membrane-
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bound form contains a transmembrane domain that anchors its extracellular domain to the 
plasma membrane. In its soluble form, it is cleaved and secreted as the N-terminal 
ectodomain and is found in very low concentrations in the circulation. The significance of 
circulating ACE2 is unclear, although levels may be increased in disease (diabetes, CKD, 
hypertension) (4,5). ACE2 has multiple substrates including kinins, apelin, neurotensin, 
dynorphin, ghrelin, amyloid and angiotensins (1-4). The best known function of ACE2  is to 
act as the physiological counterbalance of ACE providing homeostatic regulation of 
angiotensin II (Ang II) by converting Ang I to Ang-(1-9), and by converting Ang II to Ang-
(1-7), which is tissue-protective (7) (figure). ACE2 is expressed in organs important in blood 
pressure regulation (vessels, heart, kidney) as well as in the ovaries, testes, small intestine and 
lungs (1-4,7).  
Besides its enzymatic function, ACE2 has noncatalytic actions including the regulation of 
renal amino acid transport, intestinal neutral amino acid transport and pancreatic insulin 
secretion (1,2) (Figure). Some of these effects are mediated through collectrin, a homologue 
of ACE2 (8-10). Moreover, it acts as a receptor for some coronaviruses (CoV) (11,12). In 
2003 severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) was identified as 
a novel respiratory pathogen leading to a global outbreak of SARS, and in 2012 a new CoV 
was shown to cause Middle-East respiratory syndrome (MERS) (13,). In 2019, SARS-CoV-2 
was discovered as the cause of Coronavirus Disease-19 (COVID-19) (13,14). SARS CoV-2 
infection is initiated through inoculation of the respiratory tract mucosa using ACE2 acting as 
the functional receptor for cell entry, a process involving the serine protease TMPRSS2 (15-
20).  Viraemia and replication in the lung, and possibly the gastrointestinal tract, follows.  
The global impact of COVID-19 has been massive, touching everybody in some way or 
another. Following the first cases in Wuhan, reported in December 2019 (21), the infection 
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spread rapidly until in March 2020, the World Health Organization (WHO) declared COVID-
19 a pandemic (22). To date (23rd March 2020) WHO statistics indicate that more than 
14,500  people in 190 countries/areas/territories have died from SARS-CoV-2. These 
numbers are increasing daily and will continue to multiply over the next weeks and months. 
The exact source of COVID-19 is still unknown, although the natural host of the virus is 
thought to be bats (based on virus genome sequencing) and/or turtles, snakes, and pangolins 
(23-25). There has been great progress in delineating the global epidemiology of the disease, 
tracking of infected individuals and defining the clinical features that characterise the acute 
respiratory disease (26,27). However there is still a paucity of information on the molecular 
mechanisms whereby SARS-CoV-2 causes the disease and how host-pathogen interactions 
and host immune responses occur. While ACE2 and TMPRSS2 have been identified as part 
of the molecular machinery linked to SARS-Cov-2 effects, and have been suggested as 
putative therapeutic targets (15-20), there are still many unknowns about the underlying 
biology of the system. There is an urgent need to better understand the basic science of 
SARS-Cov-2-ACE2, so that disease-specific antiviral therapies can be developed. 
Considering the important role of the RAS in the pathophysiology of hypertension and 
cardiovascular and renal disease (28), it has been suggested that ACE inhibitors and Ang II 
receptor blockers (ARBs) may increase the risk of COVID-19 infection by upregulating 
ACE2 (29,30). On the other hand, it has been proposed that inhibitors of the RAS, 
particularly ARBs, may actually have therapeutic benefit in COVID-19 by targeting the host 
response to the virus (31). This is based on the fact that i) ARBs increase ACE2 
expression/activity leading to increased production of Ang-(1-7), which is tissue-protective, 
and ii) ARBs inhibit Ang II-induced inflammation and acute injury in the lungs (31,32). 
However, to date there is no convincing  clinical evidence linking  ACE inhibitors and/or 
ARBs to COVID-19 severity and mortality and further clinical research is needed (33). 
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In only 2 decades, ACE2 has emerged as an important Janus-faced multifunctional protein: 
while it promotes cardiovascular health (through its tissue-protective actions) it also 
facilitates the devastations of SARS-Cov-2 infectivity responsible for the COVID-19 
pandemic. It has also been suggested as a potential therapeutic target for SARS-CoV-2 (34-
36). To celebrate the 20-year discovery of ACE2, Clinical Science will publish a focused 
issue on ‘ACE2- a multifunctional protein’, guest edited by Prof M. Bader, Prof A. Turner 
and Dr  N. Alenina.   This issue will include state of the art review articles and research 
papers addressing the molecular and cellular biology, regulation and (patho)physiological 
functions of ACE2 in health and disease. This is perfectly aligned with the mission of the 
journal, which is to translate molecular bioscience and experimental research into medical 
insights to advance human health. 
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ACE2 is a multifunctional protein. ACE2 has enzymatic (catalytic) and non-enzymatic (non-
catalytic) functions. As a key element of the protective axis of the renin angiotensin system 
(RAS) it is responsible for production of Ang-(1-7) and Ang-(1-9). The major non-catalytic 
functions include renal amino acid transport, intestinal neutral amino acid transport and 
pancreatic insulin secretion. 
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